BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

FemHealth Focus

Acrux Advances Female Testosterone Therapy To Phase III To Address HSDD Treatment Gap

Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product Phase I and II clinical trials complete...

April 30, 2026 | News

Sun Pharmaceutical Industries Limited To Acquire Organon & Co. In $11.75 Billion All Cash Deal

Organon stockholders to receive US$ 14.00 per share in cash The deal values Organon at EV of US$ 11.75 billion Combined Business leverages complementar...

April 28, 2026 | News

Aragen Launches Women Led ChemiSHE Lab To Advance Leadership In Pharma R&D

Aragen, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) launched ChemiSHE, a first-of-its-kind chemistry synth...

April 17, 2026 | News

Alphamab Oncology Reports Phase III Success For Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed wit...

April 06, 2026 | News

Organon Asia Pacific Announces 2026 Her Health Grant Recipients To Advance Women’s Health Access

Organon Asia Pacific Cluster today announced the 2026 Her Health Grant recipients for the Asia Pacific region, marking a significant milestone in efforts t...

March 31, 2026 | News

Alphamab Oncology Initiates Phase III Study Of Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN02...

March 25, 2026 | News

Alphamab Oncology Initiates Phase 3 Study Of Bispecific ADC JSKN016 In Triple Negative Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispec...

March 23, 2026 | News

SystImmune And Bristol Myers Squibb Report Dual PFS And OS Success For Iza Bren In Phase III TNBC Trial

Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”...

March 02, 2026 | News

Mammotome Introduces In Room MRI Guided Breast Biopsy System To Improve Clinical Workflow

Mammotome, a Danaher company, announces the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System, the industry's first system designed t...

February 19, 2026 | News

Innovent Advances IBI354 Into Pivotal Phase Three Trial For HER2 Positive Advanced Breast Cancer

Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medi...

February 16, 2026 | News

Alphamab Oncology Advances JSKN003 Into Phase III Trial For HER2 Positive Advanced Colorectal Cancer

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005...

February 16, 2026 | News

Kelun Biotech Wins China Approval For Sacituzumab Tirumotecan In Advanced Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-dir...

February 09, 2026 | News

Imagion Biosystems Files FDA IND For MagSense Molecular MRI Cancer Imaging Platform

Imagion Biosystems, Ltd. (ASX: IBX) announced that the company has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Adminis...

February 06, 2026 | News

Kazia Therapeutics Reports Encouraging Early Responses For Paxalisib Combination In Advanced Triple Negative Breast Cancer

Kazia Therapeutics provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemothe...

January 29, 2026 | News

Stay Connected